Currently, dozens of MAO-B inhibitors with auxiliary beneficial properties or target affinity (e.g. antioxidative ability, inhibit Aβ aggregation, AChE inhibition, and metal chelation) have been developed by integrating pharmacophores or scaffolds from two or more molecules and were proved to undergo unique anti-AD mechanisms (Figure 1).17–21. The gene discussed is MAOB; the disease is Alzheimer disease.